All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. Nosocomial Infections in Belgium, part 2: Impact on Mortality and Costs

    KCE Reports 102 (2009)

    https://kce.fgov.be/en/nosocomial-infections-in-belgium-part-2-impact-on-mortality-and-costs

  2. Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li Fraumeni syndrome and Cowden syndrome

    KCE Reports 236 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-and-follow-up-for-women-with-familial-breastovarian-cancer-li-fraumeni-syndrome

  3. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2

    KCE Reports 243 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-diagnosis-and-follow-up-in-birt-hogg-dub%C3%A9-syndrome-familial-atypical-multiple

  4. Pharmaceutical and non-pharmaceutical interventions for Alzheimer’s Disease, a rapid assessment

    KCE Reports 111 (2009)

    https://kce.fgov.be/en/pharmaceutical-and-non-pharmaceutical-interventions-for-alzheimer%E2%80%99s-disease-a-rapid-assessment

  5. Publicly funded Practice-oriented Clinical Trials

    KCE Reports 246 (2015)

    https://kce.fgov.be/en/publicly-funded-practice-oriented-clinical-trials

  6. The non-invasive prenatal test (NIPT) for trisomy 21 – health economic aspects

    KCE Reports 222 (2014)

    https://kce.fgov.be/en/the-non-invasive-prenatal-test-nipt-for-trisomy-21-%E2%80%93-health-economic-aspects

  7. The pre-market clinical evaluation of innovative high-risk medical devices

    KCE Reports 158 (2011)

    https://kce.fgov.be/en/the-pre-market-clinical-evaluation-of-innovative-high-risk-medical-devices

  8. The value of EEG and evoked potentials in clinical practice

    KCE Reports 109 (2009)

    https://kce.fgov.be/en/the-value-of-eeg-and-evoked-potentials-in-clinical-practice

  9. Towards a better managed off-label use of drugs

    KCE Reports 252 (2015)

    https://kce.fgov.be/en/towards-a-better-managed-off-label-use-of-drugs

  10. Towards a guided and phased introduction of high-risk medical devices in Belgium

    KCE Reports 249 (2015)

    https://kce.fgov.be/en/towards-a-guided-and-phased-introduction-of-high-risk-medical-devices-in-belgium

  11. Trastuzumab in Early Stage Breast Cancer

    KCE Reports 34 (2006) 30 June (2nd edition; 22 June 2006, 1st edition)

    https://kce.fgov.be/en/trastuzumab-in-early-stage-breast-cancer

Pages